GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis…
Lila Levinson, PhD
Lila is a Science Writer at BioNews. She completed her PhD in neuroscience at the University of Washington, where she studied how the natural flexibility of the human brain can be used to promote recovery after injury. Previously, she has written about science for The Dallas Morning News and the University of Washington Computational Neuroscience Center. She enjoys exploring the Pacific Northwest and spending time with her cat, Fibonacci.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Lila Levinson, PhD
Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial…
Consistently tracking the levels of Krebs von den Lungen-6 (KL-6), a protein that can indicate lung inflammation or damage, may…
CS014, a treatment candidate for idiopathic pulmonary fibrosis (IPF), was found to be safe and well tolerated in healthy…
A Phase 2 clinical trial has begun recruiting that’s assessing the safety and efficacy of LTI-03, Rein Therapeutics’ inhaled…
GRI Bio has reached an interim enrollment goal for its Phase 2a clinical trial testing GRI-0621 — a…